NICORETTE Drug Patent Profile

Which patents cover Nicorette, and when can generic versions of Nicorette launch?

Nicorette is a drug marketed by Haleon Us Holdings and is included in four NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-two countries.

The generic ingredient in NICORETTE is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nicorette

A generic version of NICORETTE was approved as nicotine polacrilex by P AND L on March 15^th, 1999.

Summary for NICORETTE

International Patents:	44
US Patents:	3
Applicants:	1
NDAs:	4

Paragraph IV (Patent) Challenges for NICORETTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NICORETTE	Troche/Lozenge (Mini)	nicotine polacrilex	2 mg and 4 mg	022360	1	2015-12-02

US Patents and Regulatory Information for NICORETTE

NICORETTE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	NICORETTE	nicotine polacrilex	GUM, CHEWING;BUCCAL	018612-002	Feb 9, 1996		OTC	Yes	No	8,323,683
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009		OTC	Yes	No	8,501,164		Y
Haleon Us Holdings	NICORETTE	nicotine polacrilex	GUM, CHEWING;BUCCAL	020066-004	Sep 25, 2000		OTC	Yes	No
Haleon Us Holdings	NICORETTE (MINT)	nicotine polacrilex	GUM, CHEWING;BUCCAL	020066-003	Dec 23, 1998		OTC	Yes	No
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	021330-002	Oct 31, 2002		OTC	Yes	Yes
Haleon Us Holdings	NICORETTE	nicotine polacrilex	GUM, CHEWING;BUCCAL	018612-004	Sep 25, 2000		OTC	Yes	No

International Patents for NICORETTE

See the table below for patents covering NICORETTE around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	164646	NICOTINE LOZENGE COMPOSITIONS
World Intellectual Property Organization (WIPO)	2006124366
Chile	2009001025	Composicion de pastilla para chupar que comprende: a) un granulo patron con al menos: un agente tampon alcalino, un modificador de la disolucion y una carga, b) un principio activo de nicotina definido extragranular y al menos un agente tampon alcalino; procedimiento de preparacion; util para eliminar o reducir el uso de tabaco.
Argentina	071420
Canada	2608531	AROMATISANT POUR CHEWING GUMS CONTENANT UN MEDICAMENT (FLAVORING OF DRUG-CONTAINING CHEWING GUMS)
Poland	2285411

Investment Scenario and Fundamentals Analysis for NICORETTE (Transdermal Nicotine Patch)

Last updated: February 20, 2026

What is NICORETTE and its Market Context?

NICORETTE is a brand of transdermal nicotine patches used to aid smoking cessation. Originally launched in the 1990s, it is among the earliest and most recognized OTC nicotine replacement therapy (NRT) products. Its primary competitors include LA (Lance Armstrong's Bravo), NicoDerm CQ (GlaxoSmithKline), and generic nicotine patches.

The global smoking cessation market was valued at approximately $3.3 billion in 2021, with expected compound annual growth rate (CAGR) of 5.2% through 2028.[1] Growth driven by increasing awareness of smoking-related health risks, regulatory pressures, and expanding product accessibility.

Investment Opportunities and Risks

Market Opportunity

• Market Penetration: NICORETTE's brand recognition supports continued OTC sales in developed markets. Expansion into emerging markets, with less mature smoking cessation markets, presents growth potential.
• Regulatory Trends: U.S. FDA approval of new delivery systems and formulations can expand product offerings, reinforcing market dominance.
• Demographic Trends: Rising adult smoking cessation rates in North America and Europe support steady demand.

Competitive Landscape

• Generic Competition: Market share erosion by generics reduces margins but presents an opportunity if NICORETTE can maintain brand loyalty.
• New Technologies: E-cigarettes and pharmaceutical drugs (e.g., varenicline, bupropion) increase market competition but also affirm the importance of effective NRT products.

Challenges

• Regulatory Changes: Stricter nicotine regulations, including taxation and advertising restrictions, can dampen sales.
• Consumer Preferences: Shift toward alternative cessation methods, such as digital "quit smoking" apps, threaten traditional NRT approaches.
• Patent Expiry: Older formulations, like NICORETTE patches, face patent expirations, enabling generic competition which affects pricing power.

Financial Fundamentals

• Revenue Trends: NICORETTE generates steady revenues through OTC sales, with a premium pricing model supported by brand strength.

Year	Revenue (USD millions)	Growth Rate	Remarks
2019	120	3.5%	Stable with minor growth
2020	125	4.2%	Pandemic boosted health-related attention
2021	130	4.0%	Continued growth, market expansion primarily in Europe

• Margins: Typical gross margins for OTC products range from 60-75%. NICORETTE maintains approximately 65%, impacted by increased generic competition and raw material costs.
• Cost Structure: Manufacturing costs are stable; marketing and distribution expenses account for approximately 25% of revenue.
• R&D: Minimal R&D expenditure but potential investment in improved patch formulations or adjunct therapies.

Regulatory and Patent Status

• Patent Landscape: Original NICORETTE patches are off patent, but some formulations may still have proprietary delivery mechanisms protected by trade secrets or secondary patents.
• Regulatory Approvals: Approved by FDA and EMA as OTC nicotine replacement therapy. Any new formulations require regulatory review.

Strategic Considerations for Investors

• Brand Strength: NICORETTE's established presence provides near-term stable cash flow.
• Product Pipeline: Lack of recent innovation could hinder long-term growth; diversification into new formulations or delivery systems is necessary.
• Partnerships: Licensing agreements or retail partnerships enhance distribution reach, particularly in emerging markets.
• Market Trends: Increasing regulatory scrutiny complicates manufacturing and marketing efforts but may favor well-established brands with compliance capabilities.

Valuation and Investment Outlook

• Opposed to pharmaceutical drugs with high R&D costs and long approval cycles, NICORETTE's OTC model offers cash flow stability.
• Valuation multiples for consumer healthcare brands hover around 15–20x EBITDA.[2]
• For a mature, stable brand like NICORETTE, a conservative valuation would factor in growth forecasts, patent expiration timelines, and competitive positioning.

Key Risks to Monitor

• Patent expirations and the entrance of generics.
• Regulatory changes affecting nicotine sales.
• Declining consumer preference for traditional NRTs.
• Potential market disruption through alternative cessation technologies.

---

Key Takeaways

• NICORETTE capitalizes on a recognizable brand in a growing global smoking cessation market.
• Financials display stable revenues with margins conducive to steady cash flow.
• Competitive and regulatory pressures present long-term risks, especially concerning patent protection and market share.
• Potential growth hinges on innovation, geographic expansion, and adaptation to evolving consumer preferences.

---

FAQs

What is the primary revenue source for NICORETTE?
Over-the-counter nicotine patches, supported by strong brand recognition in North America and Europe.

How does patent expiration impact NICORETTE?
Patents have largely expired, increasing generic competition and putting pressure on pricing and margins.

What growth strategies are most feasible?
Expanding into emerging markets, developing new formulations, and establishing partnerships with pharmacies and retail chains.

Are regulatory risks significant?
Yes; stricter tobacco control policies and regulations on nicotine products can affect sales and marketing strategies.

Is NICORETTE a good investment for long-term growth?
Stable if maintained as a mature product, but limited upside unless innovation or market expansion occurs.

---

References

[1] Grand View Research. (2022). Smoking Cessation Market Size, Share & Trends Analysis Report.
[2] Bloomberg Intelligence. (2022). Consumer Healthcare Valuation Benchmarks.